AVTR vs AZN

The Advanced Deterministic Scorecard reveals significant financial weakness with a Piotroski F-Score of just 2/9, indicating poor profitability, deteriorating margins, and weak operating performance. Despite a reasonable Debt/Equity ratio and positive operating cash flow proxies, the company is unprofitable on a net basis (negative net margin and ROE), with declining revenue and earnings. Insider selling, a bearish technical trend, and a sharp multi-year price decline further reinforce deterioration in fundamentals. Although the forward P/E of 12.97 appears low, weak execution, shrinking profits, and lack of intrinsic value benchmarks suggest the market is pricing in continued challenges.

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.